• FDA extended Agios Pharmaceuticals' mitapivat sickle cell disease review deadline three months to February 1, 2027, from November 1, 2026.
• The agency classified updated safety information as a major amendment while evaluating whether a risk evaluation and mitigation strategy is necessary.
• Additional follow-up showed no hepatocellular injury cases matching the pattern and severity observed in mitapivat's adult thalassemia trials.
• The application has Priority Review under the accelerated approval pathway; labeling discussions continue, including potential risk mitigation requirements.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300700PRIMZONEFULLFEED9856739) on October 30, 2026, and is solely responsible for the information contained therein.